In solid tumours, high expression of the glycolytic enzyme, α-enolase (ENO1), predicts for poor patient overall survival (OS), and circulating autoantibodies to ENO1 correlate positively with diagnosis and negatively with advanced disease. Although ENO1 is one of the most highly expressed genes in acute myeloid leukaemia (AML), its potential role as a biomarker in AML or its precursor, myelodysplastic neoplasms (MDS), has not been investigated. A meta-analysis of nine AML online datasets (n = 1419 patients) revealed that high ENO1 expression predicts for poor OS (HR = 1.22, 95% CI: 1.10–1.34,p< 0.001). Additionally, when compared to AML in remission (n = 5), ENO1 protein detected by immunohistochemistry was significantly higher at diagnosis in bone marrow from both AML (n = 5,p< 0.01) and MDS patients (n = 12,p< 0.05), and did not correlate with percentage of blasts (r= 0.28,p= 0.21). AML patients (n = 34) had lower circulating levels of ENO1 autoantibodies detected by ELISA compared to 26 MDS and 18 controls (p= 0.003). However, there was no difference in OS between AML patients with high vs. low levels of anti-ENO1 autoantibodies (p= 0.77). BM immunostaining for ENO1 and patient monitoring of anti-ENO1 autoantibody levels may be useful biomarkers for MDS and AML.
在实体肿瘤中，糖酵解酶α-烯醇化酶（ENO1）的高表达预示着患者总生存期（OS）较差，且循环中针对ENO1的自身抗体水平与疾病诊断呈正相关，与疾病进展呈负相关。尽管ENO1是急性髓系白血病（AML）中表达最高的基因之一，但其作为AML或其前体骨髓增生异常肿瘤（MDS）生物标志物的潜在作用尚未得到研究。对九个AML在线数据集（n = 1419例患者）的荟萃分析显示，ENO1高表达预示着较差的OS（HR = 1.22，95% CI: 1.10–1.34，p < 0.001）。此外，与缓解期AML患者（n = 5）相比，通过免疫组织化学检测到的ENO1蛋白在AML（n = 5，p < 0.01）和MDS患者（n = 12，p < 0.05）诊断时的骨髓中显著升高，且与原始细胞百分比无相关性（r = 0.28，p = 0.21）。通过ELISA检测，AML患者（n = 34）循环中ENO1自身抗体水平低于26例MDS患者和18例对照组（p = 0.003）。然而，抗ENO1自身抗体水平高与低的AML患者之间OS无差异（p = 0.77）。骨髓ENO1免疫染色及患者抗ENO1自身抗体水平的监测可能作为MDS和AML的有用生物标志物。
肿瘤(癌症)患者之家